Recent News
On September 8, 2025 IDEAYA announced an in-person and virtual R&D Day in New York to present multiple clinical data updates across the pipeline and outline its next growth priorities. On September 4, 2025 the company reported dosing the first patient in the Phase 1/2 IDE397 plus Trodelvy combination trial for MTAP-deletion non-small cell lung cancer, noting prior expansion from urothelial cancer. The R&D Day agenda listed darovasertib neoadjuvant uveal melanoma data, IDE849 DLL3 TOP1 ADC clinical data, and IDE397 combination findings among the presentations.
Technical Analysis
ADX / DI+ / DI-: ADX at 38.22 indicates a strong trend in place. DIpositive registered a peak-and-reversal, which signals a bearish directional shift; DInegative is decreasing, which supports bullish directional pressure. The combination suggests a strong trend with conflicting directional signals that merit close monitoring against valuation levels.
MACD: MACD sits at 1.23 and recently crossed above its signal line at 1.13; MACD is increasing, which indicates bullish momentum and supports upside pressure relative to current valuation.
MRO: MRO equals 17.78 (positive), which indicates price sits above the model target and creates potential for downward mean reversion toward fair value.
RSI: RSI at 61.39 and increasing implies ongoing buying momentum without extreme overbought conditions.
Price vs Moving Averages and Bands: Last close $33.99 sits above the 20-day average $31.88, 50-day average $29.01 and 200-day average $22.91; the 12-day EMA is increasing. Bollinger upper band near $33.52 and the 52-week high $34.66 place the stock close to shorter-term resistance, while the super trend lower at $30.39 and ichimoku Tenkan/Kijun near $31.75/$30.77 provide nearby support levels.
Volume & Volatility: Today’s volume below recent averages (volume 587,433 vs 10-/50-/200-day averages) suggests thinner participation during the recent price run; 42-day beta 1.51 signals elevated responsiveness to market moves.
Fundamental Analysis
Profitability & Margins: Operating income $108,452,000 and operating margin 52.18% reflect strong operating leverage. That operating margin sits above the industry peer mean of -114.10% and peer median of 35.35% (industry peer mean/median provided), indicating materially stronger margin performance versus those peers.
Cash & Liquidity: Cash $298,927,000 and cash and short-term investments $786,894,000 provide substantial liquidity against total current liabilities $64,509,000. The current ratio equals 12.44 and the cash ratio equals 12.20, both well above typical peer metrics and supporting funding of operations without near-term financing stress.
Revenue & Earnings Growth: Total revenue $207,834,000 and YoY revenue growth 28.69% indicate meaningful top-line expansion. Earnings growth shows a QoQ contraction of 35.32% but a YoY improvement of 20.35%, reflecting quarter-to-quarter volatility alongside year-over-year recovery.
Valuation Multiples & Cash Flow: PE ratio stands at 20.28x and enterprise multiple at 14.66x. Free cash flow $142,172,000 yields 6.01%, and free cash flow converts at roughly 1.19x net income. WMDST values the stock as under-valued based on the combination of positive free cash flow yield, moderate multiples, and a strong cash buffer.
Capital Structure: Total debt $27,245,000 yields debt-to-assets of 2.30% and debt-to-equity of 2.50%, both low and consistent with a conservative leverage profile relative to typical industry ranges.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-09-30 |
| REPORT DATE: | 2025-11-04 |
| NEXT REPORT DATE: | 2026-02-03 |
| CASH FLOW | Begin Period Cash Flow | $ 115.5 M |
| Operating Cash Flow | $ 142.2 M | |
| Capital Expenditures | $ -42.00 K | |
| Change In Working Capital | $ 11.7 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 184.3 M | |
| End Period Cash Flow | $ 299.7 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 207.8 M | |
| Forward Revenue | $ -25.98 M | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | $ 1.0 M | |
| Depreciation and Amortization | $ 1.0 M | |
| Research and Development | $ 83.0 M | |
| Total Operating Expenses | $ 99.4 M | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | $ 109.5 M | |
| EBIT | $ 108.5 M | |
| Operating Income | $ 108.5 M | |
| Interest Income | $ 10.8 M | |
| Interest Expense | — | |
| Net Interest Income | $ 10.8 M | |
| Income Before Tax | $ 119.2 M | |
| Tax Provision | — | |
| Tax Rate | 21.0 % | |
| Net Income | $ 119.2 M | |
| Net Income From Continuing Operations | $ 119.2 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.55 | |
| EPS Actual | $ 1.33 | |
| EPS Difference | $ 1.88 | |
| EPS Surprise | 341.818 % | |
| Forward EPS | $ -0.68 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 1.2 B | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 1.1 B | |
| Total Current Assets | $ 802.7 M | |
| Cash and Short-Term Investments | $ 786.9 M | |
| Cash | $ 298.9 M | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | $ 805.0 K | |
| LIABILITIES | ||
| Accounts Payable | $ 18.4 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 64.5 M | |
| Net Debt | — | |
| Total Debt | $ 27.2 M | |
| Total Liabilities | $ 93.1 M | |
| EQUITY | ||
| Total Equity | $ 1.1 B | |
| Retained Earnings | $ -653.27 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 12.46 | |
| Shares Outstanding | 87.666 M | |
| Revenue Per-Share | $ 2.37 | |
| VALUATION | Market Capitalization | $ 2.4 B |
| Enterprise Value | $ 1.6 B | |
| Enterprise Multiple | 14.655 | |
| Enterprise Multiple QoQ | -193.146 % | |
| Enterprise Multiple YoY | -149.007 % | |
| Enterprise Multiple IPRWA | high: 52.77 median: 26.559 IDYA: 14.655 mean: 3.653 low: -80.476 |
|
| EV/R | 7.72 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.085 | |
| Asset To Liability | 12.729 | |
| Debt To Capital | 0.024 | |
| Debt To Assets | 0.023 | |
| Debt To Assets QoQ | -9.984 % | |
| Debt To Assets YoY | 51.649 % | |
| Debt To Assets IPRWA | high: 1.045 mean: 0.214 median: 0.075 IDYA: 0.023 low: 0.0 |
|
| Debt To Equity | 0.025 | |
| Debt To Equity QoQ | -9.993 % | |
| Debt To Equity YoY | 56.721 % | |
| Debt To Equity IPRWA | high: 1.395 mean: 0.194 median: 0.09 IDYA: 0.025 low: -0.869 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 2.165 | |
| Price To Book QoQ | 2.798 % | |
| Price To Book YoY | -11.001 % | |
| Price To Book IPRWA | high: 18.42 mean: 7.012 median: 5.8 IDYA: 2.165 low: -8.555 |
|
| Price To Earnings (P/E) | 20.276 | |
| Price To Earnings QoQ | -181.484 % | |
| Price To Earnings YoY | -136.589 % | |
| Price To Earnings IPRWA | high: 56.753 IDYA: 20.276 mean: -3.805 median: -12.252 low: -93.179 |
|
| PE/G Ratio | -0.081 | |
| Price To Sales (P/S) | 11.375 | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | high: 1129.647 mean: 73.695 median: 25.506 IDYA: 11.375 low: 0.808 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | -35.568 | |
| Forward PE/G | 0.142 | |
| Forward P/S | -91.015 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.187 | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | high: 0.438 IDYA: 0.187 mean: 0.117 median: 0.107 low: 0.0 |
|
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | high: 520.898 median: 189.366 mean: 166.152 IDYA: 0 low: -314.885 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.282 | |
| CapEx To Revenue | -0.0 | |
| CapEx To Depreciation | -0.041 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.1 B | |
| Net Invested Capital | $ 1.1 B | |
| Invested Capital | $ 1.1 B | |
| Net Tangible Assets | $ 1.1 B | |
| Net Working Capital | $ 738.1 M | |
| LIQUIDITY | ||
| Cash Ratio | 12.198 | |
| Current Ratio | 12.443 | |
| Current Ratio QoQ | 0.429 % | |
| Current Ratio YoY | -45.731 % | |
| Current Ratio IPRWA | high: 24.687 IDYA: 12.443 mean: 4.3 median: 3.195 low: 0.046 |
|
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | 0.249 | |
| Cost Of Debt | 73.559 % | |
| Interest Coverage Ratio | 4.326 | |
| Interest Coverage Ratio QoQ | -222.122 % | |
| Interest Coverage Ratio YoY | -262.128 % | |
| Interest Coverage Ratio IPRWA | high: 815.709 mean: 40.242 IDYA: 4.326 median: 4.213 low: -1538.4 |
|
| Operating Cash Flow Ratio | 1.882 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 13.816 % | |
| Revenue Growth | 2869.057 % | |
| Revenue Growth QoQ | — | |
| Revenue Growth YoY | — | |
| Revenue Growth IPRWA | IDYA: 2869.057 % high: 301.849 % mean: 8.057 % median: 4.118 % low: -259.856 % |
|
| Earnings Growth | -251.136 % | |
| Earnings Growth QoQ | -3532.226 % | |
| Earnings Growth YoY | 2034.603 % | |
| Earnings Growth IPRWA | high: 162.5 % median: -6.452 % mean: -13.118 % low: -198.545 % IDYA: -251.136 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | 52.182 % | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | high: 3270.865 % IDYA: 52.182 % median: 35.352 % mean: -114.104 % low: -8139.786 % |
|
| Return On Sales (ROS) | 52.182 % | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | high: 70.107 % IDYA: 52.182 % median: 26.151 % mean: -112.075 % low: -7977.249 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ 142.2 M | |
| Free Cash Flow Yield | 6.014 % | |
| Free Cash Flow Yield QoQ | -292.51 % | |
| Free Cash Flow Yield YoY | -447.429 % | |
| Free Cash Flow Yield IPRWA | high: 30.655 % IDYA: 6.014 % median: 0.768 % mean: 0.299 % low: -53.991 % |
|
| Free Cash Growth | -325.18 % | |
| Free Cash Growth QoQ | -13791.789 % | |
| Free Cash Growth YoY | -795.186 % | |
| Free Cash Growth IPRWA | high: 199.867 % mean: 28.151 % median: 21.696 % low: -198.468 % IDYA: -325.18 % |
|
| Free Cash To Net Income | 1.192 | |
| Cash Flow Margin | 58.43 % | |
| Cash Flow To Earnings | 1.018 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.05 | |
| Return On Assets (ROA) | 10.712 % | |
| Return On Assets QoQ | -248.038 % | |
| Return On Assets YoY | -328.791 % | |
| Return On Assets IPRWA | high: 30.5 % IDYA: 10.712 % median: -0.016 % mean: -2.274 % low: -66.968 % |
|
| Return On Capital Employed (ROCE) | 9.678 % | |
| Return On Equity (ROE) | 0.109 | |
| Return On Equity QoQ | -235.22 % | |
| Return On Equity YoY | -348.724 % | |
| Return On Equity IPRWA | high: 0.948 IDYA: 0.109 median: -0.002 mean: -0.006 low: -1.385 |
|
| DuPont ROE | 11.624 % | |
| Return On Invested Capital (ROIC) | 7.846 % | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | 5.713 % | |
| Return On Invested Capital IPRWA | high: 26.519 % IDYA: 7.846 % median: 4.232 % mean: -0.153 % low: -73.241 % |
|